Author: Nicholas Alan Clayton

new-spac
TOP-3

Oaktree II (OACB) Adds Backstops of Up to $250M to Alvotech Deal

Oaktree Acquisition Corp. II (NYSE:OACB) has added up to $250 million to its combination with biosimilar drugmaker Alvotech through two facilities to replace potential redemptions.

The backstops are made up of an $150 million standby equity purchase agreement (SEPA) from YA II PN, an affiliate of Oaktree II’s sponsor, and a binding term sheet providing $75 million to $125 million in debt from Sculptor Capital Management. ...READ MORE

dune-tradezero
new-spac
TOP-3
deal-terms-2